UTHR (United Therapeutics) EPS (Basic): $29.32 (TTM As of Mar. 2026)


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $554.59
GF Value $386.36
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics EPS (Basic)?

United Therapeutics UTHR +0.85% 88 EPS (Basic) is $29.32 as of Mar. 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.36 (Significantly Overvalued). The stock has 7 warning signs investors should review.

United Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $6.32. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $29.32.

United Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $5.82. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $27.09.

United Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $5.82. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 27.46.

During the past 12 months, United Therapeutics's average EPS without NRIGrowth Rate was 4.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 23.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 16.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, United Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 155.30% per year. The lowest was -39.40% per year. And the median was 15.45% per year.

United Therapeutics  (NAS:UTHR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

United Therapeutics EPS (Basic) Related Terms

United Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for United Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics EPS (Basic) Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.60 15.98 21.04 26.44 30.13

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.18 6.86 7.73 8.41 6.32
UTHR
88GF Score
United Therapeutics Corp UTHR
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

United Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1334.7-0)/44.300
=30.13

United Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(274.9-0)/43.500
=6.32

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $29.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $29.32 mean?
United Therapeutics (UTHR) has a EPS (Basic) of $29.32 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' EPS (Basic) too high?
United Therapeutics' current EPS (Basic) is $29.32. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' EPS (Basic) compare to VTRS and NBIX?
United Therapeutics' EPS (Basic) of $29.32 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on United Therapeutics and its competitors. United Therapeutics's current EPS (Basic) is $29.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.36, compared to a current price of $554.59 — trading 43.5% above its estimated fair value. The current EPS (Basic) is $29.32. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For United Therapeutics (UTHR), the current EPS (Basic) is $29.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $554.59 is trading 43.5% above its estimated GF Value™ of $386.36. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • EPS (Basic): $29.32
  • GF Value™: $386.36 vs. price of $554.59 (43.5% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$554.59
Price
$386.36
GF Value